These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 2353985)
1. Effect of angiotensin II on the antitumor activity and cardiotoxicity of doxorubicin. Monti E; Paracchini L; Piccinini F; Rossi C; Formelli F Cancer Lett; 1990 Apr; 50(1):79-85. PubMed ID: 2353985 [TBL] [Abstract][Full Text] [Related]
2. A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat. Storm G; van Hoesel QG; de Groot G; Kop W; Steerenberg PA; Hillen FC Cancer Chemother Pharmacol; 1989; 24(6):341-8. PubMed ID: 2791187 [TBL] [Abstract][Full Text] [Related]
3. Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529. Agen C; Bernardini N; Danesi R; Della Torre P; Costa M; Del Tacca M Cancer Chemother Pharmacol; 1992; 30(2):95-9. PubMed ID: 1600601 [TBL] [Abstract][Full Text] [Related]
4. Cardiac toxicity and antitumor activity of 4'-deoxy-4'-iodo-doxorubicinol. Danesi R; Marchetti A; Bernardini N; La Rocca RV; Bevilacqua G; Del Tacca M Cancer Chemother Pharmacol; 1990; 26(6):403-8. PubMed ID: 2171795 [TBL] [Abstract][Full Text] [Related]
5. Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl rat. van Hoesel QG; Steerenberg PA; Crommelin DJ; van Dijk A; van Oort W; Klein S; Douze JM; de Wildt DJ; Hillen FC Cancer Res; 1984 Sep; 44(9):3698-705. PubMed ID: 6744286 [TBL] [Abstract][Full Text] [Related]
6. General and cardiac toxicity of doxorubicin-loaded gelatin nanoparticles. Leo E; Arletti R; Forni F; Cameroni R Farmaco; 1997; 52(6-7):385-8. PubMed ID: 9372590 [TBL] [Abstract][Full Text] [Related]
7. Effect of flunarizine on the delayed cardiotoxicity of doxorubicin in rats. Villani F; Galimberti M; Monti E; Piccinini F; Poggi P; Lanza E; Rozza A; Favalli L Pharmacol Res; 1991 Feb; 23(2):195-202. PubMed ID: 2062794 [TBL] [Abstract][Full Text] [Related]
8. Antitumor effect, cardiotoxicity, and nephrotoxicity of doxorubicin in the IgM solid immunocytoma-bearing LOU/M/WSL rat. van Hoesel QG; Steerenberg PA; Vos JG; Hillen FC; Dormans JA J Natl Cancer Inst; 1984 May; 72(5):1141-50. PubMed ID: 6585590 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of cardiotoxicity of a new anthracycline derivative: 4'-deoxy-4'-iodo-doxorubicin. Villani F; Galimberti M; Lanza E; Rozza A; Favalli L; Poggi P Invest New Drugs; 1988 Sep; 6(3):173-8. PubMed ID: 3192383 [TBL] [Abstract][Full Text] [Related]
10. Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4'-amino-3'-hydroxy-doxorubicin. Danesi R; Bernardini N; Agen C; Costa M; Zaccaro L; Pieracci D; Malvaldi G; Del Tacca M Cancer Chemother Pharmacol; 1992; 29(4):261-5. PubMed ID: 1472260 [TBL] [Abstract][Full Text] [Related]
11. Trifluoperazine does not affect doxorubicin cardiotoxicity in the rat. Villani F; Monti E; Piccinini F; Favalli L; Rozza Dionigi A; Lanza E; Poggi P Anticancer Res; 1988; 8(4):659-63. PubMed ID: 3178155 [TBL] [Abstract][Full Text] [Related]
12. Dissociation between in vitro cytotoxicity and in vivo cardiotoxicity of two new anthracyclines: 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin and 4'-deoxy-4'-iodo-doxorubicin. Pinna A; Agen C; Di Paolo A; Innocenti F; Nardini D; Danesi R; Del Tacca M J Environ Pathol Toxicol Oncol; 1994; 13(1):25-31. PubMed ID: 7823290 [TBL] [Abstract][Full Text] [Related]
13. Improved in vivo antitumor efficacy and reduced systemic toxicity of carboxymethylpullulan-peptide-doxorubicin conjugates. Nogusa H; Hamana H; Uchida N; Maekawa R; Yoshioka T Jpn J Cancer Res; 2000 Dec; 91(12):1333-8. PubMed ID: 11123434 [TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity and cytotoxicity of the anthracycline analog 4'-deoxy-4'-iodo-doxorubicin. Danesi R; Bernardini N; Agen C; Costa M; Macchiarini P; Della Torre P; Del Tacca M Toxicology; 1991; 70(2):243-53. PubMed ID: 1763418 [TBL] [Abstract][Full Text] [Related]
15. Prevention of doxorubicin-induced cardiomyopathy by reduced glutathione. Villani F; Galimberti M; Zunino F; Monti E; Rozza A; Lanza E; Favalli L; Poggi P Cancer Chemother Pharmacol; 1991; 28(5):365-9. PubMed ID: 1914080 [TBL] [Abstract][Full Text] [Related]
16. Antitumor effects and toxicities of carboxymethylpullulan-peptide-doxorubicin conjugates. Nogusa H; Yano T; Kajiki M; Gonsho A; Hamana H; Okuno S Biol Pharm Bull; 1997 Oct; 20(10):1061-5. PubMed ID: 9353565 [TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity of doxorubicin: effects of 21-aminosteroids. Falcone G; Filippelli W; Mazzarella B; Tufano R; Mastronardi P; Filippelli A; Berrino L; Rossi F Life Sci; 1998; 63(17):1525-32. PubMed ID: 9808063 [TBL] [Abstract][Full Text] [Related]
18. Electrocardiographic and transmembrane potential effects of 5-iminodaunorubicin in the rat. Jensen RA; Acton EM; Peters JH Cancer Res; 1984 Sep; 44(9):4030-9. PubMed ID: 6744318 [TBL] [Abstract][Full Text] [Related]
19. Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats. Giri SN; Al-Bayati MA; Du X; Schelegle E; Mohr FC; Margolin SB Cancer Chemother Pharmacol; 2004 Feb; 53(2):141-50. PubMed ID: 14564477 [TBL] [Abstract][Full Text] [Related]
20. Cardiovascular effects of doxorubicin-induced toxicity in the intact Lou/M Wsl rat and in isolated heart preparations. de Wildt DJ; de Jong Y; Hillen FC; Steerenberg PA; van Hoesel QG J Pharmacol Exp Ther; 1985 Oct; 235(1):234-40. PubMed ID: 4045723 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]